Abstract
OBJECTIVE: Patients who have previously attempted suicide are at a substantially increased risk of a repeated attempt. We have conducted a cost-utility analysis of the Attempted Suicide Short Intervention Programme (ASSIP) and compared it with treatment as usual in a Flemish population.
METHODS: A closed-cohort Markov-model was used to simulate suicide over a time-horizon of 20 years in a cohort of prior suicide attempt patients. This model is used to estimate Incremental Cost Effectiveness Ratios (ICERs) from societal and healthcare perspectives. A separate 'tipping-point' scenario was included, where the treatment effectiveness regresses over time.
RESULTS: ASSIP is shown to be a dominant strategy from the societal perspective and cost-effective from a healthcare perspective: the ICER after 10 years is € 1,133 and after 20 years € 304. In the tipping-point scenario, an regression of up to 82,7% after the intervention remains cost-effective, assuming an ICER threshold of € 44000 per QALY.
CONCLUSION: Our study found that ASSIP is cost-effective in the Flemish region, saving both healthcare costs and societal expenses over time. Implementing ASSIP could provide significant economic and health benefits within 10 years, making it a valuable investment for improving mental health care.
| Original language | English |
|---|---|
| Pages (from-to) | 897-904 |
| Number of pages | 8 |
| Journal | Expert Review of Pharmacoeconomics & Outcomes Research |
| Volume | 25 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2 May 2025 |
Bibliographical note
Publisher Copyright:© 2025 Informa UK Limited, trading as Taylor & Francis Group.